Developer docs
API playgroundTry for free, no card

Search company profiles

Iterative Health

Full company profile

uuid0002h7l

Namestring
Iterative Health
Legal namestring
Iterative Scopes, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Iterative Health (legal entity Iterative Scopes, Inc., founded 2017, headquartered at 675 Massachusetts Avenue, Cambridge, MA) operates an AI-enabled, community-embedded clinical research site network spanning 100+ research sites across North America, Europe, India, and Australia. The company serves pharmaceutical sponsors, biotech firms, and contract research organizations (CROs) that need to execute Phase II-IV trials in gastroenterology, hepatology, obesity, and cardiology, and serves as an operational partner to community specialty practices that want to participate in research without building internal infrastructure. At the center of the offering is a centralized operating layer that provides regulatory documentation, training, budgeting, AI-driven pre-screening, and trial management, combined with proprietary AI capabilities including SKOUT (an FDA-cleared real-time AI polyp detection system), AI-ES and AI-ESe (automated endoscopic scoring for ulcerative colitis developed with Eli Lilly), and machine-learning patient matching built on de-identified endoscopic video and EHR data from across the network. Reported performance metrics include 2x faster site activation, 3-3.4x higher patient enrollment versus published industry benchmarks, 74-day median activation timelines (versus 120-171 day benchmarks), and high-performing endoscopists detecting 1 additional adenoma per 4.5 patients with SKOUT assistance.

The business model rests on three revenue streams: (1) clinical research site network services sold via enterprise agreements to pharma/CRO sponsors, typically multi-year and quote-based, with deal scope set by therapeutic area, enrollment targets, and geographic reach; (2) SKOUT AI device licensing, negotiated annually with gastroenterology practices and ambulatory surgery centers; and (3) patient recruitment services for specific trials, structured as master services agreements (e.g., a $3 million equity-linked recruitment engagement with Palisade Bio for the PALI-2108 ulcerative colitis Phase 2 trial). Go-to-market runs through three channels: enterprise field sales targeting sponsors and CROs, channel/MSO partnerships with major specialty provider networks (GI Alliance and Cardinal Health, One GI and Webster Equity Partners, US Heart & Vascular), and direct licensing of SKOUT to GI practices. The company is venture-backed (approximately $257 million disclosed across Seed/Series A/B/C), led by founder/CEO Jonathan Ng, and has expanded its C-suite through 2025-2026 with a President/CFO hire from GI Alliance, a CMO for Hepatology & Obesity, and a promotion to COO.

Short descriptiontext

Iterative Health operates an AI-enabled, community-embedded clinical research site network of 100+ sites serving pharmaceutical sponsors and CROs across gastroenterology, hepatology, obesity, and cardiology, combining FDA-cleared SKOUT AI polyp detection, AI-ES scoring, and centralized operations that outperform industry trial benchmarks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, AI polyp detection, gastroenterology clinical trials, site network management, endoscopic AI scoring
Industry6 codes
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAKAEAA
General Gastroenterology
SECONDARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Custom Computer Programming Services541511
  • Software Publishers5132
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
Clinical Research Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Research Site Network Services
TypeSubscription Recurring
Description

Iterative Health generates revenue by providing a network of high-performing clinical research sites to pharmaceutical sponsors, biotech companies, and CROs. The company embeds clinical research infrastructure into community-based physician practices, offering centralized operations, staffing, AI technology, and trial management services. Revenue comes from clinical trial agreements where sponsors pay for site access, patient enrollment, and trial execution performance.

businesswire.com
2SKOUT AI Device Licensing
TypeLicensing Royalties
Description

FDA-cleared AI polyp detection technology licensed to gastroenterology practices and ambulatory surgery centers. The company provides the AI software as a device that enhances colonoscopy quality, generating licensing revenue from healthcare providers who adopt the technology for clinical use.

iterative.health
3Patient Recruitment Services
TypeProfessional Services
Description

Revenue generated through master services agreements to accelerate patient recruitment for specific clinical trials, such as the partnership with Palisade Bio for their PALI-2108 Phase 2 trial enrollment. Services include AI-powered screening and operational support.

in.investing.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise clinical trial services with customized scope based on therapeutic area, trial complexity, site network access, and performance requirements.
ModelOtherBilling cadenceMulti-year contract
Notes

Clinical research services priced through custom enterprise agreements with pharmaceutical sponsors and CROs. No public pricing available; negotiations based on trial specifications, enrollment targets, and geographic scope.

businesswire.com
2AI-assisted colonoscopy technology for gastroenterology practices and ASCs.
ModelOtherBilling cadenceAnnual
Notes

SKOUT licensing negotiated directly with healthcare providers. No public pricing disclosed; healthcare facilities contact sales for demonstration and pricing information.

iterative.health
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SKOUT
Description

Real-time AI-powered polyp detection technology for colonoscopy procedures, FDA-cleared AI-assisted device for GI care.

iterative.health
Core offering1 text field

Iterative Health operates a global multispecialty clinical research site network spanning 100+ sites across North America, Europe, India, and Australia, embedded in community-based physician practices for GI, hepatology, obesity, and cardiology trials. The company also develops and commercializes proprietary AI technology, most notably SKOUT® (FDA-cleared real-time AI polyp detection for colonoscopy) and AI-ES/AI-ESe (automated endoscopic scoring systems for ulcerative colitis clinical trials), sold to pharma sponsors, CROs, and healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 2x faster site activation, reducing startup timelines by up to 3 months compared to industry benchmarks
+5 more records
Product overview1 text field

Iterative Health is a healthcare technology and services company offering a unified portfolio centered on accelerating clinical research. The core offering combines a global multispecialty Site Network spanning over 100 research sites with proprietary AI technology. Key products include SKOUT®, an FDA-cleared real-time AI polyp detection device for colonoscopy, and AI-powered clinical trial tools including AI-ES and AI-ESe for automated endoscopic scoring in ulcerative colitis. The company also provides AI-enabled pre-screening technology and centralized operational support services that power the site network model, enabling sponsors to accelerate trial execution across gastroenterology, hepatology, obesity, and cardiology therapeutic areas.

Product and service4 records
1SKOUT® Real-Time AI Polyp Detection
CategoryAI-Assisted Medical Device Software
Description

FDA-cleared real-time AI-powered polyp detection system for colonoscopy procedures that uses advanced computer vision to identify clinically significant lesions and sessile serrated polyps during endoscopy, helping clinicians improve adenoma detection rates. Licensed to gastroenterology practices and ambulatory surgery centers seeking to improve colonoscopy quality and meet ACG/ASGE quality recommendations.

2Iterative Health Site Network (Clinical Research Services)
CategoryClinical Research Services
Description

Global multispecialty clinical research network embedded in community care settings, spanning over 100 research sites across North America, Europe, India, and Australia. Provides pharmaceutical sponsors, biotech firms, and CROs with centralized access to high-performing sites for GI, hepatology, obesity, and cardiology clinical trials, delivering 2x faster site activation and 3x higher enrollment rates versus industry benchmarks. Includes centralized operations, expert staffing, regulatory support, budgeting, training, and pre-screening workflows.

3AI-ES (AI Endoscopic Score) and AI-ESe (Extended Endoscopic Score)
CategoryAI Clinical Trial Endpoints Software
Description

Machine learning-based systems that automate endoscopic inflammation scoring for ulcerative colitis clinical trials, improving reliability and reproducibility of disease severity assessment compared with manual human-based central reading. AI-ESe is the extended version that characterizes overall burden of inflammation with higher detail. Sold as a clinical trial endpoint technology to pharmaceutical sponsors.

4AI-Powered Patient Recruitment Services
CategoryClinical Trial Recruitment Services
Description

Patient recruitment services powered by machine learning algorithms that process de-identified endoscopic videos and EHR data from the 100+ GI community sites to identify eligible clinical trial participants. Delivered through master services agreements to pharmaceutical sponsors, reducing screen failure rates and accelerating enrollment timelines.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Acquisition of three cardiology research sites in Beaumont, Port Arthur, and Waco, Texas from NextStage Clinical Research. Bourne Partners served as exclusive financial advisor on the transaction. Sites bring experienced cardiovascular research teams, established community provider relationships, and active cardiology trial programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Patient recruitment partnership with $3 million investment from Iterative Health affiliate. Palisade Bio sold shares to Iterative Health affiliate and entered master services agreement for patient recruitment support for Phase 2 trial of PALI-2108 in ulcerative colitis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Strategic partnership to advance community-based cardiovascular research. USHV clinical research sites join Iterative Health's global site network spanning 100+ sites across 3 continents. USHV sites gain access to Iterative Health's centralized operational backbone, end-to-end clinical research operations support, technology innovation, and business development capabilities. Partnership expands Iterative Health beyond GI, hepatology, and obesity into cardiology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-21
Description

Collaboration on AI-powered endoscopic scoring for ulcerative colitis clinical trials. Partnership developed AI-Enabled Endoscopic Score (AI-ES) and extended AI-ESe, with data presented at ECCO 2025. Collaboration aims to improve reliability and reproducibility of endoscopic outcomes in clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

Strategic partnership with One GI (top physician-led MSO and Webster Equity Partners portfolio company) to advance clinical research as a core ancillary service. One GI's network of 34 clinics across 6 states with 13 active research sites becomes exclusive mainstay in Iterative Health's global site network. Collaboration builds on two years of consistent industry-leading results.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-23
Description

GI Alliance (a Cardinal Health company and the nation's leading gastroenterology network) formed strategic partnership to expand access to clinical trials across community-based practices. Integration of GIA's 21 active research sites conducting over 80 Phase II-IV trials into Iterative Health's Site Network, creating a combined network of more than 70 locations across US and Europe. Partnership represents a first-of-its-kind alliance to power the largest GI-focused clinical research network.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-10
Description

AI partnership to improve patient selection, clinical assessments, and treatment pathways for inflammatory bowel disease (IBD) using machine learning. Partnership leverages AI-driven endoscopic assessments to advance patient selection and clinical evaluation in IBD clinical trials. Takeda's goal is evidence-based decision-making on therapy utilization in the real world.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-24
Description

Partnership to advance next-generation IBD treatment. Foundation's patient data repository enriches Iterative Health's AI models for GI clinical research, supporting the development of novel therapies for inflammatory bowel disease.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-02-08
Description

AI-driven data sharing agreement to advance IBD clinical trials. Agreement deployed artificial intelligence to improve efficiency and accelerate drug development for inflammatory bowel disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iterative Health

Clinical Research Servicesiterative.health

Iterative Health operates an AI-enabled, community-embedded clinical research site network of 100+ sites serving pharmaceutical sponsors and CROs across gastroenterology, hepatology, obesity, and cardiology, combining FDA-cleared SKOUT AI polyp detection, AI-ES scoring, and centralized operations that outperform industry trial benchmarks.

What Iterative Health does

Iterative Health (legal entity Iterative Scopes, Inc., founded 2017, headquartered at 675 Massachusetts Avenue, Cambridge, MA) operates an AI-enabled, community-embedded clinical research site network spanning 100+ research sites across North America, Europe, India, and Australia. The company serves pharmaceutical sponsors, biotech firms, and contract research organizations (CROs) that need to execute Phase II-IV trials in gastroenterology, hepatology, obesity, and cardiology, and serves as an operational partner to community specialty practices that want to participate in research without building internal infrastructure. At the center of the offering is a centralized operating layer that provides regulatory documentation, training, budgeting, AI-driven pre-screening, and trial management, combined with proprietary AI capabilities including SKOUT (an FDA-cleared real-time AI polyp detection system), AI-ES and AI-ESe (automated endoscopic scoring for ulcerative colitis developed with Eli Lilly), and machine-learning patient matching built on de-identified endoscopic video and EHR data from across the network. Reported performance metrics include 2x faster site activation, 3-3.4x higher patient enrollment versus published industry benchmarks, 74-day median activation timelines (versus 120-171 day benchmarks), and high-performing endoscopists detecting 1 additional adenoma per 4.5 patients with SKOUT assistance.

The business model rests on three revenue streams: (1) clinical research site network services sold via enterprise agreements to pharma/CRO sponsors, typically multi-year and quote-based, with deal scope set by therapeutic area, enrollment targets, and geographic reach; (2) SKOUT AI device licensing, negotiated annually with gastroenterology practices and ambulatory surgery centers; and (3) patient recruitment services for specific trials, structured as master services agreements (e.g., a $3 million equity-linked recruitment engagement with Palisade Bio for the PALI-2108 ulcerative colitis Phase 2 trial). Go-to-market runs through three channels: enterprise field sales targeting sponsors and CROs, channel/MSO partnerships with major specialty provider networks (GI Alliance and Cardinal Health, One GI and Webster Equity Partners, US Heart & Vascular), and direct licensing of SKOUT to GI practices. The company is venture-backed (approximately $257 million disclosed across Seed/Series A/B/C), led by founder/CEO Jonathan Ng, and has expanded its C-suite through 2025-2026 with a President/CFO hire from GI Alliance, a CMO for Hepatology & Obesity, and a promotion to COO.

Iterative Health firmographics

Firmographics
Name
Iterative Health
Legal name
Iterative Scopes, Inc.
Website
https://iterative.health
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
Iterative Health operates an AI-enabled, community-embedded clinical research site network of 100+ sites serving pharmaceutical sponsors and CROs across gastroenterology, hepatology, obesity, and cardiology, combining FDA-cleared SKOUT AI polyp detection, AI-ES scoring, and centralized operations that outperform industry trial benchmarks.
Ownership category
akta.pro rank

Iterative Health industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAKAEAA
General Gastroenterology
SECONDARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Clinical research services
  • AI polyp detection
  • Gastroenterology clinical trials
  • Site network management
  • Endoscopic AI scoring

Where Iterative Health is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Iterative Health business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Site Network Services: Iterative Health generates revenue by providing a network of high-performing clinical research sites to pharmaceutical sponsors, biotech companies, and CROs. The company embeds clinical research infrastructure into community-based physician practices, offering centralized operations, staffing, AI technology, and trial management services. Revenue comes from clinical trial agreements where sponsors pay for site access, patient enrollment, and trial execution performance.
  2. SKOUT AI Device Licensing: FDA-cleared AI polyp detection technology licensed to gastroenterology practices and ambulatory surgery centers. The company provides the AI software as a device that enhances colonoscopy quality, generating licensing revenue from healthcare providers who adopt the technology for clinical use.
  3. Patient Recruitment Services: Revenue generated through master services agreements to accelerate patient recruitment for specific clinical trials, such as the partnership with Palisade Bio for their PALI-2108 Phase 2 trial enrollment. Services include AI-powered screening and operational support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise clinical trial services with customized scope based on therapeutic area, trial complexity, site network access, and performance requirements.
OtherAnnualAI-assisted colonoscopy technology for gastroenterology practices and ASCs.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Iterative Health product offering

Product offering

Core offering

Iterative Health operates a global multispecialty clinical research site network spanning 100+ sites across North America, Europe, India, and Australia, embedded in community-based physician practices for GI, hepatology, obesity, and cardiology trials. The company also develops and commercializes proprietary AI technology, most notably SKOUT® (FDA-cleared real-time AI polyp detection for colonoscopy) and AI-ES/AI-ESe (automated endoscopic scoring systems for ulcerative colitis clinical trials), sold to pharma sponsors, CROs, and healthcare providers.

Product overview

Iterative Health is a healthcare technology and services company offering a unified portfolio centered on accelerating clinical research. The core offering combines a global multispecialty Site Network spanning over 100 research sites with proprietary AI technology. Key products include SKOUT®, an FDA-cleared real-time AI polyp detection device for colonoscopy, and AI-powered clinical trial tools including AI-ES and AI-ESe for automated endoscopic scoring in ulcerative colitis. The company also provides AI-enabled pre-screening technology and centralized operational support services that power the site network model, enabling sponsors to accelerate trial execution across gastroenterology, hepatology, obesity, and cardiology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • SKOUT: Real-time AI-powered polyp detection technology for colonoscopy procedures, FDA-cleared AI-assisted device for GI care.

Products and services

  • SKOUT® Real-Time AI Polyp Detection FDA-cleared real-time AI-powered polyp detection system for colonoscopy procedures that uses advanced computer vision to identify clinically significant lesions and sessile serrated polyps during endoscopy, helping clinicians improve adenoma detection rates. Licensed to gastroenterology practices and ambulatory surgery centers seeking to improve colonoscopy quality and meet ACG/ASGE quality recommendations.
  • Iterative Health Site Network (Clinical Research Services) Global multispecialty clinical research network embedded in community care settings, spanning over 100 research sites across North America, Europe, India, and Australia. Provides pharmaceutical sponsors, biotech firms, and CROs with centralized access to high-performing sites for GI, hepatology, obesity, and cardiology clinical trials, delivering 2x faster site activation and 3x higher enrollment rates versus industry benchmarks. Includes centralized operations, expert staffing, regulatory support, budgeting, training, and pre-screening workflows.
  • AI-ES (AI Endoscopic Score) and AI-ESe (Extended Endoscopic Score) Machine learning-based systems that automate endoscopic inflammation scoring for ulcerative colitis clinical trials, improving reliability and reproducibility of disease severity assessment compared with manual human-based central reading. AI-ESe is the extended version that characterizes overall burden of inflammation with higher detail. Sold as a clinical trial endpoint technology to pharmaceutical sponsors.
  • AI-Powered Patient Recruitment Services Patient recruitment services powered by machine learning algorithms that process de-identified endoscopic videos and EHR data from the 100+ GI community sites to identify eligible clinical trial participants. Delivered through master services agreements to pharmaceutical sponsors, reducing screen failure rates and accelerating enrollment timelines.

Quantifiable outcome

  • 2x faster site activation, reducing startup timelines by up to 3 months compared to industry benchmarks
  • +5 more outcomes

Companies that use Iterative Health

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Iterative Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Iterative Health partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

  • NextStage Clinical ResearchcoreStrategic or Co-development Partner · 14 May 2026Acquisition of three cardiology research sites in Beaumont, Port Arthur, and Waco, Texas from NextStage Clinical Research. Bourne Partners served as exclusive financial advisor on the transaction. Sites bring experienced cardiovascular research teams, established community provider relationships, and active cardiology trial programs.
  • Palisade BiominorStrategic or Co-development Partner · 9 April 2026Patient recruitment partnership with $3 million investment from Iterative Health affiliate. Palisade Bio sold shares to Iterative Health affiliate and entered master services agreement for patient recruitment support for Phase 2 trial of PALI-2108 in ulcerative colitis.
  • US Heart & VascularcoreStrategic or Co-development Partner · 27 March 2026Strategic partnership to advance community-based cardiovascular research. USHV clinical research sites join Iterative Health's global site network spanning 100+ sites across 3 continents. USHV sites gain access to Iterative Health's centralized operational backbone, end-to-end clinical research operations support, technology innovation, and business development capabilities. Partnership expands Iterative Health beyond GI, hepatology, and obesity into cardiology.
  • Eli LillycoreTechnology or Integration · 21 February 2026Collaboration on AI-powered endoscopic scoring for ulcerative colitis clinical trials. Partnership developed AI-Enabled Endoscopic Score (AI-ES) and extended AI-ESe, with data presented at ECCO 2025. Collaboration aims to improve reliability and reproducibility of endoscopic outcomes in clinical trials.
  • One GIcoreStrategic or Co-development Partner · 26 August 2025Strategic partnership with One GI (top physician-led MSO and Webster Equity Partners portfolio company) to advance clinical research as a core ancillary service. One GI's network of 34 clinics across 6 states with 13 active research sites becomes exclusive mainstay in Iterative Health's global site network. Collaboration builds on two years of consistent industry-leading results.
  • GI AllianceflagshipStrategic or Co-development Partner · 23 April 2025GI Alliance (a Cardinal Health company and the nation's leading gastroenterology network) formed strategic partnership to expand access to clinical trials across community-based practices. Integration of GIA's 21 active research sites conducting over 80 Phase II-IV trials into Iterative Health's Site Network, creating a combined network of more than 70 locations across US and Europe. Partnership represents a first-of-its-kind alliance to power the largest GI-focused clinical research network.
  • TakedacoreTechnology or Integration · 10 January 2025AI partnership to improve patient selection, clinical assessments, and treatment pathways for inflammatory bowel disease (IBD) using machine learning. Partnership leverages AI-driven endoscopic assessments to advance patient selection and clinical evaluation in IBD clinical trials. Takeda's goal is evidence-based decision-making on therapy utilization in the real world.
  • Crohn's & Colitis FoundationminorStrategic or Co-development Partner · 24 October 2024Partnership to advance next-generation IBD treatment. Foundation's patient data repository enriches Iterative Health's AI models for GI clinical research, supporting the development of novel therapies for inflammatory bowel disease.
  • PfizercoreTechnology or Integration · 8 February 2022AI-driven data sharing agreement to advance IBD clinical trials. Agreement deployed artificial intelligence to improve efficiency and accelerate drug development for inflammatory bowel disease.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Iterative Health competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

Iterative Health social profiles

Digital presence

Iterative Health compliance and trust

Trust signal

Compliance2 records

Iterative Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iterative Health leadership team

Management profile

Number of profiles

Profiles8 records

Iterative Health subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Iterative Health funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iterative Health M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iterative Health

What does Iterative Health do?

Iterative Health operates a global multispecialty clinical research site network spanning 100+ sites across North America, Europe, India, and Australia, embedded in community-based physician practices for GI, hepatology, obesity, and cardiology trials. The company also develops and commercializes proprietary AI technology, most notably SKOUT® (FDA-cleared real-time AI polyp detection for colonoscopy) and AI-ES/AI-ESe (automated endoscopic scoring systems for ulcerative colitis clinical trials), sold to pharma sponsors, CROs, and healthcare providers.

Is Iterative Health a public or private company?

Iterative Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Iterative Health founded?

Iterative Health was founded in 2021. It employs 101 to 250 people.

Where is Iterative Health based?

Iterative Health is headquartered in Cambridge, United States, in the North America region.

How does Iterative Health make money?

Three revenue lines are on record. Clinical Research Site Network Services are the primary driver. The others are SKOUT AI Device Licensing and patient Recruitment Services.

Does Iterative Health have an API?

No public API is recorded for Iterative Health.

What industry is Iterative Health in?

Iterative Health's product category is Clinical Research Services. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogIterative Health and Gastroenterology Associates of New Jersey Partner to Expand Patient Access to Advanced GI ResearchIterative Health, a healthcare technology and services company, announced a strategic partnership with Gastroenterology Associates of New Jersey (GANJ) to integrate clinical research into community GI care across New Jersey. Iterative Health will serve as GANJ's definitive research partner, with two newly established sites in Toms River and Clifton, NJ joining Iterative Health's global network of 110+ sites. The collaboration leverages GANJ's network of 28 locations and 60+ healthcare professionals to expand patient access to cutting-edge GI therapies within their own communities.AijournIterative Health Acquires Cardiology Sites from NextStage Clinical ResearchIterative Health announced the acquisition of three cardiology research sites from NextStage Clinical Research, located in Beaumont, Port Arthur, and Waco, Texas, with Bourne Partners serving as exclusive financial advisor on the transaction. The acquisition directly extends Iterative Health's cardiology strategy and adds proven sites in a high-need therapeutic area where cardiovascular trials can expand patient access to advanced care. The company, which operates more than 100 sites across three continents, plans to leverage its 250-person team and proprietary AI tools to support the newly acquired sites in advancing cardiovascular research.Pulse 2.0Iterative Health: Cardiology Site Acquisition Expands Texas Clinical Research NetworkIterative Health announced the acquisition of three cardiology research sites from NextStage Clinical Research, expanding its cardiovascular clinical trial capabilities in Beaumont, Port Arthur, and Waco, Texas. The acquired sites bring experienced cardiovascular research teams, established community provider relationships, and active cardiology trial programs to Iterative Health's growing network. The company operates more than 100 clinical research sites across three continents and utilizes AI and engineering tools to accelerate patient recruitment and optimize trial design.BeinsureIterative Health raises $77 mn in Series C funding to expand AI-driven trial networkIterative Health, a healthcare technology and clinical research company, closed a $77 million Series C financing round led by Intrepid Growth Partners and GV (Google Ventures), with participation from EDBI, Insight Partners, Obvious Ventures, and a large family office. The funding will support expansion beyond gastroenterology and hepatology into cardiology and obesity research while growing its clinical trial network internationally across North America, Europe, India, and Australia. The company claims its network of over 100 research sites delivers site activation twice as fast and reduces startup timelines by up to three months compared to industry benchmarks.Business Wire BlogIterative Health Reports Expanded Trial Performance Data at Digestive Disease Week 2026, Demonstrating Consistent Outperformance of Industry Benchmarks at Double the ScaleIterative Health presented updated trial performance data at Digestive Disease Week 2026, showing enrollment rates more than 3x industry benchmarks across a doubled network scale. The analysis covered UC and Crohn's disease trials, with a per-study randomization rate of 0.33 patients per site per month versus 0.10 benchmark. Results support expanding the model to additional disease areas.Clinical Trials ArenaIterative Health banks $77m to level up AI-driven clinical research techIterative Health has raised $77 million in a Series C funding round led by Google Ventures and Intrepid Growth Partners to scale its AI-powered clinical research network. The company will use the proceeds to expand its platform applications into cardiology and obesity therapeutic areas while continuing geographic expansion, with its current network spanning over 100 research sites across four continents and partnerships with more than 40 biotech, pharma, medical device companies and CROs.citybizIterative Health Raises $77 Million Series C to Scale AI-Driven Clinical Trial NetworkIterative Health has raised $77 million in Series C financing led by Intrepid Growth Partners and GV (Google Ventures) to expand its AI-enabled clinical research network and accelerate clinical trial execution across multiple therapeutic areas. The company, which embeds clinical research into physician practices through centralized operations and proprietary AI tools, reports its network now spans over 100 sites across North America, Europe, India, and Australia with partnerships involving more than 40 pharmaceutical, biotech, and contract research organizations. The funding will support expansion into additional therapeutic areas including cardiology and obesity research while deepening geographic presence and strengthening partnerships with healthcare provider organizations.Business Wire BlogIterative Health Closes $77 Million Series C to Accelerate the Future of Clinical ResearchIterative Health, a healthcare technology and services company headquartered in Cambridge, Massachusetts, has closed a $77 million Series C financing round led by Intrepid Growth Partners and GV (Google Ventures), with participation from new investor EDBI and existing investors Insight Partners and Obvious Ventures. The funding will support expansion into new therapeutic areas including cardiology and obesity beyond the company's existing gastroenterology and hepatology focus, as well as continued geographic growth of its clinical research network spanning over 100 sites globally. The company reports that its network delivers 2x faster site activation and 3x higher patient enrollment rates compared to industry benchmarks for IBD trials.TamradarIterative Health Raises $77M Series C for AI Trial NetworkIterative Health raised $77M in Series C funding led by Intrepid Growth Partners and GV, valuing the Boston-based clinical trial site network at about $1.3B. The capital will expand into cardiology and obesity, with its AI-powered site network achieving 3.4x higher enrollment than benchmarks. The company plans to scale its global network of over 100 sites.Venture Capital Access OnlineIterative Health Closes $77 Million Series C to Accelerate the Future of Clinical ResearchIterative Health closed a $77 million Series C round led by Intrepid Growth Partners and GV. The funding will support expansion into cardiology and obesity, and geographic growth. The company's network includes over 100 sites and partners with 40+ organizations.